Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics is a promising company with a positive outlook due to its innovative pipeline and favorable recent developments. The company has shown positive results in its potential treatment for Idiopathic Pulmonary Fibrosis and has successfully resolved previous issues with the FDA. Its financing, enrollment progress, and upcoming Phase 2 data release suggest a promising future for Rein Therapeutics. However, there are still risks to consider, such as financing and regulatory challenges, but overall, Rein Therapeutics presents a compelling risk-reward opportunity for investors in the biopharmaceutical sector.

Bears say

Rein Therapeutics is facing a challenging outlook, with limited treatments in its pipeline and a dilutive financing structure that has resulted in significant stock dilution. While recent investments from healthcare-focused investors are promising, the company must now focus on successfully enrolling and completing its RENEW Phase 2 trial for LTI-03 in Idiopathic Pulmonary Fibrosis. The company's progress in this area will be crucial to determining its ultimate success and may result in a potential price target revision to better reflect the company's true value.

RNTX has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 2 analysts, RNTX has a Strong Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.